Apyx Medical Corporation (APYX) Fair Value 2026

APYX · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-08-27, Apyx Medical Corporation (APYX) trades at $3.00. QOC: 6.3/10. Value Trap Risk: 13/100 (SAFE). 1/13 models active.

Key Facts

Ticker
APYX
Price
$3.00
Quality Score
6.3/10
Value Trap Risk
13/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give APYX?

1 Intrinsic Value Models vs. Current Price ($3.00)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.91 -69.8%

All Models Active

All 1 models are displayed above.

What Is Apyx Medical Corporation (APYX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Apyx Medical Corporation's intrinsic value is estimated at $0.91. Trading at its current price of $3.00, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -69.8%.

What Do the Models Say About APYX?

1 of 13 models are currently active for APYX. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does APYX Rank in Medical Devices?

Among 157 Medical Devices stocks, APYX ranks #76 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to healthcare company businesses. For Apyx Medical Corporation, metrics like pipeline depth and stage distribution provide important context that general-purpose valuation models may underweight.

Is APYX a Value Trap?

CirclFi's Value Trap algorithm assigns APYX a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Apyx Medical Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Apyx Medical Corporation scores 6.3 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every APYX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across APYX's 1 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Apyx Medical Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

ECORelectroCore, Inc.QOC 6.4PETVPetVivo Holdings, Inc.QOC 6.3RDGLVivos Inc.QOC 6.4AHCOAdaptHealth Corp.QOC 6.3BFLYButterfly Network, Inc.QOC 6.4OFIXOrthofix Medical Inc.QOC 6.2NUWENuwellis, Inc.QOC 5.3ICCMIceCure Medical LtdQOC 2.8SNWVSANUWAVE Health, Inc.QOC 7.4IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: ECOR · PETV · RDGL · AHCO · BFLY · OFIX · NUWE · ICCM · SNWV · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to APYX?

6 companies across all industries closest to APYX’s Quality of Company score of 6.3/10.

STROSutro Biopharma, Inc.QOC 6.3SCTHSecureTech Innovations, Inc.QOC 6.3FLGFlagstar Bank, National AssociationQOC 6.4TCRXTScan Therapeutics, Inc.QOC 6.4CTMXCytomX Therapeutics, Inc.QOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: STRO · SCTH · FLG · TCRX · CTMX · NVDA

Where Does APYX Sit in CirclFi's Medical Devices Rankings?

APYX is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Apyx Medical Corporation’s Valuation?

What is Apyx Medical Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Apyx Medical Corporation (APYX). The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is APYX overvalued or undervalued right now?

At $3.00, 0 of 1 active models suggest APYX may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Apyx Medical Corporation's business model in Medical Devices.

What does a Quality of Company score of 6.3 mean for APYX?

Apyx Medical Corporation's QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on APYX?

CirclFi analyzes APYX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is APYX a value trap in 2026?

Apyx Medical Corporation's Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Apyx Medical Corporation (APYX) a Quality of Company score of 6.3/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/APYX/ · Methodology
Primary sources for this APYX valuation
  • Financial statements: Apyx Medical Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0000719135) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for APYX as of ; valuations recomputed .